Navigation Links
HUYA Bioscience Int'l Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
Date:3/3/2008

Team includes Peter Kowey, pioneer of anti-arrhythmic drugs/devices in U.S., and Eric Topol, one of top 10 cited biomedical researchers over past

decade

SAN FRANCISCO, March 3 /PRNewswire/ -- IBC Conference -- HUYA Bioscience International (HUYA), the leader in U.S./China pharmaceutical co-development, today announced the clinical advisory team for its new anti-arrhythmic compound, HBI-3000. The new compound is set to begin enrollment under the final Phase I clinical trial protocol after successful completion of three previous Phase I protocols in China. The advisory team consists of world-class biomedical researchers who will provide guidance to HUYA and its Chinese partner, Shanghai Institute of Materia Medica (SIMM), throughout the course of an innovative U.S./China co-development process for HBI-3000.

The advisory team consists of:

Peter R. Kowey, M.D., Professor of Medicine and Clinical Pharmacology at Jefferson Medical College and a pioneer in the development of many anti-arrhythmic drugs and anti-tachycardia devices;

Eric Topol, M.D., Chief Academic Officer for Scripps Health, former chairman of Cardiovascular Medicine at the Cleveland Clinic for 15 years and recognized by the Institute of Scientific Information as one of the top 10 cited researchers in medicine over the past decade;

Benedict R. Lucchesi, Ph.D., Professor of Pharmacology at the University of Michigan Medical School Department of Pharmacology for more than 40 years and contributor to more than 370 publications in basic pharmacology and drug development;

Denis Roy, M.D., Montreal Heart Institute, Professor and Chair of the Department of Medicine at the University of Montreal and Principal Investigator of the recently completed Atrial Fibrillation and Congestive Heart Failure multi-center international trial;

Jefferson L. Anderson, M.D., Professor of Medicine, University of Utah and Chief of Cardiology, Intermountain Medical Center, a major contributor to cardiovascular research over a broad area including anti-arrhythmic therapies, genetic polymorphisms and new risk factors for cardiovascular disease.

Stanley Nattel, M.D., Paul-David Chair in Cardiovascular Electrophysiology, Professor of Medicine, University of Montreal, Director, Electrophysiology Research Program Montreal Heart Institute Research Center, University of Montreal.

According to Mireille Gingras, Ph.D., CEO of HUYA, this top-notch advisory team exemplifies the level of excellence HUYA is bringing to the co-development process between HUYA and its partners at SIMM in China. "We're thrilled to have each of these renowned scientists on our advisory team and look forward to working closely with them on this promising new anti-arrhythmic compound, HBI-3000. Our tightly integrated co-development effort with our Chinese partners represents a true breakthrough in Sino-American pharmaceutical development and we're proud to undertake that effort with this outstanding group of advisors."

HBI-3000 clinical milestones in China

In a separate announcement today, HUYA discussed the completion of enrollment and evaluation under three Phase I clinical trial protocols in China of its anti-arrhythmic compound, HBI-3000, a balanced multi-ion channel blocker, originally licensed from SIMM. The data from the trials -- in combination with pre-clinical data generated separately and in collaboration by HUYA and SIMM -- support a desirable safety profile; most significantly, a lack of life-threatening pro-arrhythmic activity.

Anti-arrhythmic drugs are used today to treat patients with atrial fibrillation (AF), a serious condition that afflicts 5.6 million Americans. Anti-arrhythmic agents have also been used for the treatment of ventricular arrhythmias, although most have failed to demonstrate a survival advantage, and in some cases carry significant safety risk.

The main concern with anti-arrhythmic drugs is an increased risk of sudden death (Torsade de Pointes) in patients with underlying organic heart disease such as coronary artery disease, prior history of myocardial infarction and heart failure. A large subset of individuals with atrial and ventricular arrhythmias suffers from these conditions, precluding treatment with most existing anti-arrhythmic drugs. Development of safe anti-arrhythmic agents for use in these patients is needed. Pre-clinical data developed by HUYA and its Chinese partner, along with the Chinese clinical trial data suggest that HBI-3000 may have safety advantages over other anti-AF agents and exhibits broad spectrum ion channel inhibition without pro-arrhythmic activity that suggests it may also be safer to use in treatment of ventricular arrhythmias.

HUYA's innovative co-development model

HUYA was one of the first companies to recognize the potential of China as a source for novel pre-clinical and clinical stage compounds and pioneered an innovative co-development model. HUYA partners with Chinese research institutions and pharmaceutical companies to leverage and extend their research efforts, accelerate development, and provide a bridge into the U.S. development process and the biopharma market. This model contrasts with that of some large pharmaceutical companies whose approach is to start their own research facilities in China hoping to tap its large biotech talent pool, or that of smaller competitors with "one-off" single compound strategies.

One of the key differentiators of HUYA's approach is the assembly of a world-class team of scientific and clinical advisors for each promising new compound, such as that assembled for the HBI-3000. This team is available to collaborate with its Chinese partners and is then able to leverage and extend these efforts as the compounds enter the development process in the U.S., streamlining the process and mitigating risk.

About HUYA

HUYA is the leader in Sino-American pharmaceutical co-development, formed to meet the global need for new, untapped sources of pre-clinical and clinical stage compounds. HUYA identifies promising new compounds in China and partners with Chinese research institutions to leverage and extend their research efforts, accelerate development, and provide a bridge into the U.S. development process and the biopharma market. With three strategic offices in China, a broad Chinese compound portfolio, and exclusive agreements with premier Chinese biotech centers, HUYA has pioneered the most innovative and productive approach for pharmaceutical co-development between the U.S. and China. Further information about the company is available at http://www.huyabio.com.

Contact:

USA:

Jan Tuttleman, Ph.D.

Vice President, Marketing

HUYA Bioscience International

(858) 798-8800

jtuttleman@huyabio.com

China:

Wen Chen, M.S., MBA

EVP China Operation and Chief Representative

HUYA Bioscience International

86 (21) 51323312

wchen@huyabio.com

Media Contacts:

Amy Berry

(415) 793-2258

amyeberry@comcast.net

Juliet Travis

(510) 452-3771

juliet@travispr.com


'/>"/>
SOURCE HUYA Bioscience International
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
3. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
5. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
6. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
7. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
8. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
9. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host its fiscal ... Friday, November 3, 2017, beginning at 7:00 a.m. (CDT) ... a.m. (CDT) / 9:30 a.m. (EDT). In ... guidance for 2018, Hill-Rom executives will also highlight the ... long-range financial outlook through 2020. ...
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017 /PRNewswire/ ... health and big data solutions, today announced that its MyDario product is ... your local TV listings for when The Dr. Oz Show airs in ... The nine-time ... month. ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... advisory services for healthcare compliance program management, will showcase a range of technology ... Association for Assisted Living (NCAL) Convention and Expo to be held October 14–18, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally ... care, have expanded their existing home health joint venture through an agreement, effective ... operating a joint venture home health company with Asante, delivering clinically integrated care, ...
(Date:10/12/2017)... Malvern, PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best ... New York City on October 11, 2017. , The annual award competition recognizes editorial ...
Breaking Medicine News(10 mins):